95 related articles for article (PubMed ID: 9797872)
21. Expression of the human multidrug resistance gene mdr1 in leukemic cells and its application in studying P-glycoprotein antagonists.
Fu J; Chen Z; Cen J; Ruan C
Chin Med J (Engl); 2000 Mar; 113(3):228-31. PubMed ID: 11775252
[TBL] [Abstract][Full Text] [Related]
22. Coexpression of a multidrug-resistance gene (MDR1) and herpes simplex virus thymidine kinase gene as part of a bicistronic messenger RNA in a retrovirus vector allows selective killing of MDR1-transduced cells.
Sugimoto Y; Hrycyna CA; Aksentijevich I; Pastan I; Gottesman MM
Clin Cancer Res; 1995 Apr; 1(4):447-57. PubMed ID: 9816003
[TBL] [Abstract][Full Text] [Related]
23. Expression of the human multidrug resistance and glucocerebrosidase cDNAs from adeno-associated vectors: efficient promoter activity of AAV sequences and in vivo delivery via liposomes.
Baudard M; Flotte TR; Aran JM; Thierry AR; Pastan I; Pang MG; Kearns WG; Gottesman MM
Hum Gene Ther; 1996 Jul; 7(11):1309-22. PubMed ID: 8818718
[TBL] [Abstract][Full Text] [Related]
24. Retroviral-mediated transfer and functional expression of multidrug resistance gene in human placenta mesenchymal stem cells.
Han LY; Ye MZ; Li YP; Wang BW; Wang Q; Zhao SH; Li HL
Chin Med J (Engl); 2008 May; 121(9):800-5. PubMed ID: 18701045
[TBL] [Abstract][Full Text] [Related]
25. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells.
Allay JA; Galipeau J; Blakley RL; Sorrentino BP
Stem Cells; 1998; 16 Suppl 1():223-33. PubMed ID: 11012166
[TBL] [Abstract][Full Text] [Related]
26. Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease.
Sugimoto Y; Aksentijevich I; Murray GJ; Brady RO; Pastan I; Gottesman MM
Hum Gene Ther; 1995 Jul; 6(7):905-15. PubMed ID: 7578409
[TBL] [Abstract][Full Text] [Related]
27. Gene therapy: is IL2RG oncogenic in T-cell development?
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Nature; 2006 Sep; 443(7109):E5; discussion E6-7. PubMed ID: 16988660
[TBL] [Abstract][Full Text] [Related]
28. Generation of mammalian cells stably expressing multiple genes at predetermined levels.
Liu X; Constantinescu SN; Sun Y; Bogan JS; Hirsch D; Weinberg RA; Lodish HF
Anal Biochem; 2000 Apr; 280(1):20-8. PubMed ID: 10805516
[TBL] [Abstract][Full Text] [Related]
29. Efficient detection of thirty-seven new IL2RG mutations in human X-linked severe combined immunodeficiency.
Niemela JE; Puck JM; Fischer RE; Fleisher TA; Hsu AP
Clin Immunol; 2000 Apr; 95(1 Pt 1):33-8. PubMed ID: 10794430
[TBL] [Abstract][Full Text] [Related]
30. [Gene therapy using anticancer drug-resistance genes].
Sugimoto Y
Gan To Kagaku Ryoho; 1999 Jan; 26(1):1-9. PubMed ID: 9987494
[TBL] [Abstract][Full Text] [Related]
31. Efficient ablation by immunotoxin-mediated cell targeting of the cell types that express human interleukin-2 receptor depending on the internal ribosome entry site.
Kobayashi T; Kida Y; Kaneko T; Pastan I; Kobayashi K
J Gene Med; 2001; 3(5):505-10. PubMed ID: 11601764
[TBL] [Abstract][Full Text] [Related]
32. In vivo drug-selectable markers in gene therapy.
Sugimoto Y; Tsuruo T
Leukemia; 1997 Apr; 11 Suppl 3():552-6. PubMed ID: 9209454
[TBL] [Abstract][Full Text] [Related]
33. Retroviral transduction of IL2RG into CD34(+) cells from X-linked severe combined immunodeficiency patients permits human T- and B-cell development in sheep chimeras.
Tsai EJ; Malech HL; Kirby MR; Hsu AP; Seidel NE; Porada CD; Zanjani ED; Bodine DM; Puck JM
Blood; 2002 Jul; 100(1):72-9. PubMed ID: 12070011
[TBL] [Abstract][Full Text] [Related]
34. Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.
Aksentijevich I; Cardarelli CO; Pastan I; Gottesman MM
Clin Cancer Res; 1996 Jun; 2(6):973-80. PubMed ID: 9816258
[TBL] [Abstract][Full Text] [Related]
35. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
36. Comparison of bicistronic retroviral vectors containing internal ribosome entry sites (IRES) using expression of human interleukin-12 (IL-12) as a readout.
Harries M; Phillipps N; Anderson R; Prentice G; Collins M
J Gene Med; 2000; 2(4):243-9. PubMed ID: 10953915
[TBL] [Abstract][Full Text] [Related]
37. The selectable marker neo gene down-regulates gene expression from retroviral vectors containing an internal ribosome entry site.
Byun J; Kim JM; Robbins PD; Kim S
Gene Ther; 1998 Oct; 5(10):1441-4. PubMed ID: 9930351
[TBL] [Abstract][Full Text] [Related]
38. Induction of chemoresistance in a cultured canine cell line by retroviral transduction of the canine multidrug resistance 1 gene.
Matsuura S; Koto H; Ide K; Fujino Y; Setoguchi-Mukai A; Ohno K; Tsujimoto H
Am J Vet Res; 2007 Jan; 68(1):95-100. PubMed ID: 17199425
[TBL] [Abstract][Full Text] [Related]
39. Poor expression of MDR1 transgene in HeLa cells by bicistronic Moloney murine leukemia virus-based vector.
Zaboikin MM; Schuening FG
Hum Gene Ther; 1998 Oct; 9(15):2263-75. PubMed ID: 9794210
[TBL] [Abstract][Full Text] [Related]
40. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression.
Sokolic RA; Sekhsaria S; Sugimoto Y; Whiting-Theobald N; Linton GF; Li F; Gottesman MM; Malech HL
Blood; 1996 Jan; 87(1):42-50. PubMed ID: 8547675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
